Behr M,Warren S,Salamon H, Hopewell P, Ponce dLA. 1999.Transmission of Mycobacterium
Tuberculosis from patients smear negative for acid-fast bacilli. Lancet 353:444-9.
Brust JCM, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL. 2011. Culture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa. PLoS ONE 6(1): e15841. doi:10.1371/journal.pone.0015841.Accessed on October 20,2014
Brust JCM, Berman AR., ZaltaB, HaramatLB.… Gandhi NR.2013.Chest Radiograph Findings and Time to Culture Conversion in Patients with Multidrug-Resistant Tuberculosis and HIV in Tugela Ferry, South Africa. PLoS ONE 8(9): e73975. doi:10.1371/journal.pone.0073975.Accessed on October 19, 2014.
Central Statistical Agency Addis Ababa, Ethiopia & ICF International Calverton, Maryland, USA. 2012. Ethiopia Demographic and Health Survey, 2011. Retrieved from http://measuredhs.com/pubs/pdf/FR255/FR255.pdf. Accessed on October 23,2014.
Chan ED, Laurel V, Strand M J, Chan JF, Huynh MLN. 2004. Treatment and outcome analysis of 205 patients with multidrug- resistant tuberculosis. Am J R espirCrit Care Med 169: 1103–1109.
Cox HS, Kalon S, Allamuratova S, Sizaire V, Tigay ZN.2007 Multidrug-Resistant Tuberculosis Treatment Outcomes in Karakalpakstan,Uzbekistan.PLoS ONE 2(11): e1126. doi:10.1371/journal.pone.0001126.Accessed on March 16, 2015.
Daniel, W.W. 1999. A foundation for analysis in health science. Biostatistics. Seventh edition. Georgia State University, New York, UAS. John Wiley & Sons, Ltd.
David w. Hosmer, Stanley L. 2013.Applied Logistic Regression. Third Edition.
Diacon AH, Pym A, G robusch M, Patientia R, Rustomjee R. 2009.Thediarylquino line TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360: 2397–405.
Federal Democratic Republic of Ethiopia Population Census Commission (FDRE-PCC). 2007. Summary and Statistical report of the population and housing census result.
FMOH-E.2008.Health management information system national guideline for health facilities in Ethiopia
FMOH-E 2014 report, unpublished.
FMOH-E. 2013.Training material on programmatic management of drug resistant tuberculosis in Ethiopia for GHWs facilitators’ guide July, 2012.Addis Ababa Ethiopia
FMOH-E. Guidelines for clinical and programmatic management of TB, TB/HIV and leprosy in Ethiopia 5th edition march. Addis Ababa Ethiopia.
FMOH-E 2015 report, unpublished.
FMOH-E 2018 report, unpublished.
Gandhi NR, Andrews JR, Brust JC, Montreuil R, Weissman D, Heo M, Moll AP, Friedland GH, Shah NS.2012. Risk factors for mortality among MDR and XDR-TB Patients in a high HIV-prevalence setting in South Africa.Int J Tuberc Lung Disease16 (1):90-7. doi: 10.5588/ijtld.11.0153.Accessed on October 19,2014.
Hafkin J, Modongo C, Newcomb C, Lowenthal.2013.Impact of the human Immunodeficiency
virus on early multidrug-resistant tuberculosis treatment Outcomes in Botswana.
DOIhttp://dx.doi.org/10.5588/ijtld.12.0100.Accessed on Novmber3, 2014.
He GX, Xie YG, Wang LX, Borgdorff MW, van der Werf MJ. 2010. Follow-Up of Patients with Multidrug Resistant Tuberculosis Four Years after Standardized First-Line Drug Treatment. PLoS ONE 5(5): e10799. doi:10.1371/journal.pone.0010799.Accessed on November3, 2014.
HernandezE, Cook V, Kunimoto D, Elwood R, Black W. 2 004.Transmission of tuberculosis
from smear negative patients: a molecular epidemiology study. Thorax 59: 286–90.
Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V. 2 006.Time to sputum
Culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Me d 144: 650–659.
Isaakidis P, Cox HS, Varghese B, Montaldo C, Da Silva E. 2011.Ambulatory Multi-Drug Resistant Tuberculosis Treatment Outcomes in a Cohort of HIV-Infected Patients in a Slum Setting in Mumbai, India.PLoS ONE 6(12): e28066. doi:10.1371/journal.pone.0028066.Accessed on March 16, 2015.
Kathryn Schnippel, Sydney Rosen, Kate Shearer, Neil Martinson, Lawrence Long, Ian Sanne and Ebrahim Variava.2013. Costs of inpatient treatment for multi-drug-resistant tuberculosis.Tropical Medicine and International Health 18: no 1 pp 109 –116.
Kliiman K and Altraja A, 2009. Predictors of poor treatment outcome inmulti- and extensively drug-resistant pulmonary TB.EurRespir J 2009; 33: 1085–1094
DOI: 10.1183/09031936.00155708.Accessed on January 11, 2015.
Kurbatova EV, Gammino VM, Bayona J, Becerra MC, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP.2012. Predictors of sputum cultureconversion among patients treated for multidrug-resistant tuberculosis.International Journal of Tuberculosis and Lung disease 16(10):1335–1343.
Laerson KF, Thorpe LE, Leimane V, Weyer K, Mitnik CD, Riekstina V, Zarovska E, Rich ML, Fraser HSF, Alarcon E, Cegielski JP, Grzemska M, Gupta R, Espinal M .2005.Treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 9: 640-645
Loveday M, Wallengren K, Voce A,Margot B, Reddy T, MasterI,BrustJChaiyachatiK,andPadayatchi N.2012. Comparing early treatment outcomes of MDR-TB in a decentralised setting with a centralised setting. Int J Tuberc Lung Dis.16 (2): 209–215. doi:10.5588/ijtld.11.0401.Accessed onJanuary1, 2015.
Mpagama SG, Heysell SK, Ndusilo ND, Kumburu HH, Lekule IA.2013. Diagnosis and Interim Treatment Outcomes from the First Cohort of Multidrug Resistant Tuberculosis Patients in Tanzania. PLo S ONE 8(5):e62034. doi:10.1 371/journal.p one.006203. Accessed on October 24, 2014.
Oladimeji O, Isaakidis P, Obasanya OJ, Eltayeb O, Khogali M. 2014. Intensive-Phase Treatment Outcomes among Hospitalized Multidrug-Resist antTuberculosis Patients: Results from a Nationwide Cohort in Nigeria. PLoS ONE 9(4): e94393. doi:10.1371/journal.pone.0094393.accessed on October 27, 2014.
Podewils LJ, Maria Tarcela S. Gler, Maria Imelda Quelapio Michael P. Chen.2013. Patterns of Treatment Interruption among Patients with Multidrug-Resistant TB (MDR TB) and Association with Interim and Final Treatment Outcomes. PLoS ONE 8(7): e70064. doi:10.1371/journal.pone.0070064.Accessed on January 10, 2015.
Qazi F, Khan U, Khowaja S, Javaid M, Ahmed A. 2011. Predictors of delayed culture conversion in patients treated for multidrug-resistant tuberculosisin Pakistan. IntJTuberc Lung Dis 15: 1556–60.
Rieder H. 1996. Sputum smear conversionduring d irectly observed treatment for tuberculosis. Tuber L ung D is 77: 124–9.
Rodriguez M, M onedero I, Caminero J, Encarnacio´ n M, Dominguez Y.2013. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Int J T berc Lung Dis 17:520–5.
Satti H, McLaughlin MM, Hedt-Gauthier B, Atwood SS, Omotayo DB. 2012. Outcomes of Multidrug-Resistant Tuberculosis Treatment with Early Initiation of Antiretroviral Therapy for HIV Co-Infected Patients in Lesotho. PLoS ONE 7(10): e46943. doi:10.1371/journal.pone.0046943
Salaniponi F , Christensen J, Gausi F , Kwanjana J, H arries A. 1999. Sputum smear status at two months and subsequent treatment outcome in new patients with smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis 3: 1047–8.
SeungK J., OmatayoDB., KeshavjeeS, FurinJ J., Farmer P E., Hind S. 2009. Early Outcomes of MDR-TB Treatment in a High HIV-Prevalence Setting in Southern Africa. PLoSONE 4(9): e7186. doi:10.1371/journal.pone.0007186.Accessed on November2, 2014.
Singla R, Osman M , Khan N , A l-Sharif N, Al-Sayegh M. 2003.Factors Predicting persistent
Sputumsmears positivity among pulmonary tuberculosis patients 2 months after treatment. Int J Tuberc Lung Dis 7: 58–64.
Singla R, Sarin R, Khalid U, Mathuria K, Singl a N. 2009. Seven-year DOTS-Plus pilot
experience in India: results, constraints and issues. Int J Tuberc Lung Dis 13: 976–81.
Temple B, AyakakaI, OgwangS,NabanjjaH, ……….and Edward C. 2008.Rate and Amplification of Drug Resistance among Previously-Treated Patients with Tuberculosis. Clin Infect Dis.
Wells C, Cegielski JP, Nelson L, Laserson K, Holtz T.2007. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Disease196 (Suppl 1):S86–107.
WHO. 2008. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2008.402
WHO .2008. Anti-tuberculosis Drug resistance in the World. Report No.4. (WHO⁄HTM⁄ TB ⁄ 2008.394) WHO, Geneva. http://www.who.int/tb/publications/2008/drs_report4_26feb08.pdf.Accessedon October 3,2014
WHO.2010. Multidrug and extensively drug-resistant TB (M/XDR-TB): Global Report on Surveillance and Response. Geneva, Switzerland.
WHO.2013. Multidrug-resistant tuberculosis Global TB report Update www.who.int/tb
WHO.2014. Multidrug and extensively drug-resistant TB: Global Report on Surveillance and Response. Geneva, Switzerland.
WHO.2018. Multidrug and extensively drug-resistant TB: Global Report on Surveillance and Response. Geneva, Switzerland.
Yew WW, Chan CK, Chau CH, Tam CM, Leung CC.2000. Outcomes of patients with multidrug - resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin -containing regimens. Chest 117: 744–51.
|